Iowa Attorney General Wins $1 Million Judgement Against “Scam Stem Cell Treatment Company”

A court ordered major penalties and reimbursements after deceptive stem cell treatments were marketed to Iowans, particularly older residents.

Key findings

  • An Iowa court found Travis Broughton and two Omaha-based stem cell companies liable for roughly $1 million tied to umbilical cord stem cell injections marketed in Iowa.
  • The ruling includes ~$810,477 in reimbursements to 76 patients, along with civil and enhanced penalties tied to violations involving older Iowans.
  • The court also permanently barred the defendants from engaging in the same conduct in Iowa again, and allowed reimbursement of the state’s reasonable attorney fees and costs.

An Iowa court has ruled against Travis Broughton and his Omaha-based stem cell businesses Omaha Stem Cells, LLC and Regenerative Medicine and Anti-Aging Institutes of Omaha, LLC, finding the defendants liable for approximately $1 million, according to the Iowa Attorney General’s office.

What the court ordered
The Attorney General’s office says Mr. Broughton and the companies operated in Iowa generally from 2018 to 2020 and marketed and sold unproven umbilical cord stem cell injections. The court found the defendants liable for approximately $1 million, including:

  • Reimbursements: Full reimbursement to 76 Iowans who received injections, totaling $810,477.
  • Civil penalties: The court assessed what it described as the maximum penalty of $40,000 per violation, totaling $160,000.
  • Enhanced penalties: The law allows enhanced penalties of up to $5,000 per violation when violations are committed against older Iowans, and the court imposed the maximum, for a total of $20,000.

The court also permanently prohibited Mr. Broughton and his companies from engaging in the same conduct in Iowa again and ordered reimbursement of the State’s reasonable attorney fees and costs.

“If you come into our state and scam Iowans you will be held accountable,” said Attorney General Bird. “We are grateful for the court’s decision in this case where a snake oil salesman preyed on vulnerable Iowans who desperately needed a cure and relief and used that against them for profit. It’s disgusting and wrong. We fight to make sure that these con artists are held responsible.”

Allegations in the case
According to the Attorney General’s office, the lawsuit accused Mr. Broughton and his companies of deceptively promoting umbilical cord stem cell treatments as cures for multiple conditions, including COPD (chronic obstructive pulmonary disease), joint pain, Alzheimer’s disease, and aging.

The office says the treatments were referred to as “regenerative medicine,” and that the defendants specifically targeted older Iowans and used testimonial videos in sales seminars that promoted the effectiveness of the treatments.

Read the full ruling here.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

If you found this post helpful, would you mind sharing it? ⬇️ 

Related:

Based on their results in Korea/Japan, they received a Phase 3 fast track in the USA, and hope to show true cartilage regeneration. Potentially historic moment for the industry coming.
Long-term follow-up suggests ProTrans may help preserve insulin production, with results varying by dose.
The proposed legislation, if passed, will allow culture-expanded autologous mesenchymal stem cell therapies in the Cowboy State.
Based on Phase IIa trial data where 85% of patients had resolution of chronic fatigue over 20% with placebo, the company will now offer its cord blood cell therapy outside of the Phase III soon.
The company's autologous cartilage repair product will now be reimbursed under national health insurance, WOMAC scores improved better than hyaluronic acid injections.

The Latest:

A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.
GwoXi’s FDA filing aims to support cell therapy and exosome developers with a standardized, traceable stem cell source.
The lipid microbubble platform aims to enhance cell therapy manufacturing, adapted from its clinically validated ultrasound imaging tech.
The company says its platform may fundamentally change how cartilage loss and degenerative joint disease is treated globally.
The new registry aims to address evidence gaps and track long-term outcomes for orthobiologic treatments.
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
The collaboration will assess whether robotic automation can help scale up cell therapy manufacturing while maintaining GMP standards.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
With the right secured for stem cell potency, Longeveron is continuing its path forward with clinical trials for several mesenchymal stem cell indications.
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling scalable, GMP-compliant cell production.

Discover more from Regen Report

Subscribe now to keep reading and get access to the full archive.

Continue reading

Stay updated on Regenerative Medicine